Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China-Reference-Cited by-同舟云学术

Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China

Published:2024-01 Issue: Volume:196 Page:113439
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Li Jian,Zhang Jun,Zhang Yanqiao,Qiu Haibo,Zhou Yanbing,Zhou Yongjian,Zhang Xinhua,Zhou Ye,Zhu Yuping,Li Yong,Wang Ming,Shen Kuntang,Tao Kaixiong,Wu Xin,Wang Haijiang,Zhang Bo,Ling Jiayu,Ye Yingjiang,Wu Xingye,Qu Hongyan,Ma Yue,Jiao Xuelong,Zheng Hualong,Jin Jiejie^ORCID,Liu Zhuo,Tan Ming,Fang Yong,Zhang Peng,Zhang Nan,Lei Cheng,Cai Zhaolun^ORCID,Liang Bin,Peng Zhangyan,Huang Zhao,Dong Juan,Shen Lin

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): gastrointestinal stromal tumors (GISTs) version 1. 2022.

2. Gastrointestinal stromal tumors (GIST) related emergencies;Sorour;Int J Surg,2014

3. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies;Søreide;Cancer Epidemiol,2016

4. Incidence of gastrointestinal stromal tumor in Chinese urban population: a national population-based study;Xu;Cancer Med,2021

5. Evaluating and reporting gastrointestinal stromal tumors after imatinib mesylate treatment;Dennis;Open Pathol J,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis;World Journal of Clinical Oncology;2024-08-24

2. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib;Frontiers in Pharmacology;2024-07-24

3. Differential diagnosis of gastrointestinal stromal tumors versus leiomyomas by special stains;2024-03-29

4. Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution;Cell Death & Disease;2024-03-05